Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- Resource Type
- Article
- Source
- In
The Lancet Diabetes & Endocrinology May 2019 7(5):356-367 - Subject
Primary Research Articles - Language
- ISSN
- 2213-8587